TABLE 4.
Endometrial pathology by group
| Placebo | ISP | |
|---|---|---|
| Endometrial biopsy performed | 7/103 (6.8%) | 9/121 (7.4%) |
| Benign endometrial pathology, any type | 6/7 (85.7%) | 9/9 (100%) |
| Benign, not otherwise specified | 4/7 (57.1%) | 5/9 (55.6%) |
| Atrophic | 2/7 (28.6%) | 3/9 (33.3%) |
| Proliferative | 0/7 (0%) | 1/9 (11.1%) |
| Endometrial hyperplasia / endometrial cancer | 1/7 (14.3%) a | 0/9 (0%) |
p> 0.05 (NS) by Fisher’s exact test for all comparisons
a
Participant with postmenopausal bleeding and EEC=12 mm, endometrial biopsy: atypical endometrial hyperplasia; final pathology from hysterectomy: Stage IB endometrial cancer